Collegium Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 05, 2020 at 04:20 pm EST
Share
Collegium Pharmaceutical, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating income was USD 19.626 million compared to operating loss of USD 6.375 million a year ago. Net income was USD 11.286 million compared to net loss of USD 6.109 million a year ago. Basic earnings per share from continuing operations was USD 0.33 compared to basic loss per share from continuing operations of USD 0.18 a year ago. Diluted earnings per share from continuing operations was USD 0.32 compared to diluted loss per share from continuing operations of USD 0.18 a year ago. For the nine months, operating income was USD 41.236 million compared to operating loss of USD 21.375 million a year ago. Net income was USD 19.794 million compared to net loss of USD 20.521 million a year ago. Basic earnings per share from continuing operations was USD 0.58 compared to basic loss per share from continuing operations of USD 0.62 a year ago. Diluted earnings per share from continuing operations was USD 0.56 compared to diluted loss per share from continuing operations of USD 0.62 a year ago.
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
COLLEGIUM PHARMACEUTICAL, INC. 
